References
- Miller DR . A tribute to Sidney Farber–the father of modern chemotherapy. Br. J. Haematol.134 (1), 20–26 (2006).
- Frei III E . Combination cancer therapy: presidential address. Cancer Res.32, 2593–2607 (1972).
- Kohler G Milstein C . Continuous cultures of fused cells secreting antibody of predefined specificity. Nature256, 495–497 (1975).
- Jones TD Carter PJ Plűckthun A et al. The INNs and outs of antibody nonproprietary names. mAbs8 (1), 1–9 (2016).
- Trail PA Willner D Lasch SJ et al. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science261, 212–215 (1993).
- Sedlacek H-H Seemann G Hoffmann D et al. Antibodies as carriers of cytotoxicity. In : Contributions to Oncology. HuberHQueisserW ( Eds). Karger, Basel (1992).
- Chari RVJ Miller ML Widdison WC . Antibody–drug conjugates: an emerging concept in cancer therapy. Angew. Chem. Int. Ed.53, 3796–3827 (2014).
- Bross PF Beitz J Chen G et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin. Cancer Res.7, 1490–1496 (2001).
- Petersdorf SH Kopecky KJ Slovak M et al. A Phase 3 study of gemtuzumab ozogamicin during induction and post-consolidation therapy in younger patients with acute myeloid leukemia. Blood121, 4854–4860 (2013).
- Senter PD Sievers EL . The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat. Biotechnol.30, 631–637 (2012).
- Lambert JM Chari RVJ . Ado-trastuzumab emtansine (T-DM1): an antibody–drug conjugate (ADC) for HER2-positive breast cancer. J. Med. Chem.57, 6949–6964 (2014).
- Damelin M Bankovich A Park A et al. Anti-EFNA4 calicheamicin conjugates effectively target triple-negative breast and ovarian tumor-initiating cells to result in sustained tumor regressions. Clin. Cancer Res.21, 4165–4173 (2015).
- Saunders LR Bankovich AJ Anderson WC et al. A DLL3-targeted antibody–drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci. Transl. Med.7, 302ra136 (2015).
- Whiteman KR Noordhuis P Walker R et al. The antibody–drug conjugate (ADC) IMGN779 is highly active in vitro and in vivo against myeloid leukemia (AML) with Flt3-ITD mutations. Blood124, Abstract 2321 (2014).
- Elgersma RC Coumans RG Huijbregts T et al. Design, synthesis, and evaluation of linker-duocarmycin payloads: toward selection of HER2-targeting antibody–drug conjugate SYD985. Mol. Pharmaceutics12, 1813–1835 (2015).
- Kelly KR Chanan-Khan A Somlo G et al. Indatuximab ravtansine (BT062) in combination with lenalidomide and low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma: clinical activity in len/dex-refractory patients. Blood122 (21), 758–758 (2013).
- Ansell SM . Brentuximab vedotin. Blood124 (22), 3197–3200 (2014).
- Műller P Martin K Theurich S et al. Microtubule-depolymerizing agents used in antibody–drug conjugates induce antitumor immunity by stimulation of dendritic cells. Cancer Immunol. Res.2 (8), 741–755 (2014).
- Műller P Kreuzaler M Khan T et al. Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade. Sci. Transl. Med.7, 315ra188 (2015).
- Moore KN Martin LP Seward SM et al. Preliminary single agent activity of IMGN853, a folate receptor alpha (FRα)-targeting antibody–drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Phase I trial. J. Clin. Oncol.33 (15 Suppl.), 5518 (2015).